Published in J Phys Chem B on January 28, 2010
Aurora A kinase activity influences calcium signaling in kidney cells. J Cell Biol (2011) 1.10
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity (2010) 4.21
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 3.12
HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. Nature (2012) 3.08
Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. J Cell Biol (2002) 3.05
A Ran signalling pathway mediated by the mitotic kinase Aurora A in spindle assembly. Nat Cell Biol (2003) 2.86
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol (2005) 2.41
Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A (2008) 2.33
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis (2008) 2.31
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther (2008) 2.07
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition. J Cell Sci (2004) 1.93
PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res (2011) 1.87
The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol (2007) 1.84
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol (2010) 1.69
On the role of aurora-A in centrosome function. Oncogene (2002) 1.68
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother (2009) 1.63
A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity (2011) 1.58
DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun (2007) 1.53
Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer (2008) 1.52
Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells. J Immunol (2012) 1.51
The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation. EMBO Rep (2006) 1.49
The evolution and population genetics of the ALDH2 locus: random genetic drift, selection, and low levels of recombination. Ann Hum Genet (2004) 1.49
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res (2006) 1.48
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A (2010) 1.46
APC/Fizzy-Related targets Aurora-A kinase for proteolysis. EMBO Rep (2002) 1.45
Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res (2011) 1.38
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol (2006) 1.35
CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res (2012) 1.34
TACC1-chTOG-Aurora A protein complex in breast cancer. Oncogene (2003) 1.33
Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One (2011) 1.33
Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res (2008) 1.32
Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. J Immunol (2010) 1.30
PRP4 is a spindle assembly checkpoint protein required for MPS1, MAD1, and MAD2 localization to the kinetochores. J Cell Biol (2007) 1.27
Spindle pole regulation by a discrete Eg5-interacting domain in TPX2. Curr Biol (2008) 1.26
Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol (2010) 1.25
CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage. Cell Cycle (2005) 1.18
Fundamental reaction mechanism and free energy profile for (-)-cocaine hydrolysis catalyzed by cocaine esterase. J Am Chem Soc (2009) 1.15
Proteomic investigation of phosphorylation sites in poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase. J Proteome Res (2009) 1.14
Fluorinated N,N-dialkylaminostilbenes repress colon cancer by targeting methionine S-adenosyltransferase 2A. ACS Chem Biol (2013) 1.14
Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity. J Immunol (2012) 1.13
Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res (2009) 1.13
FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients. Cell Div (2007) 1.13
Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. Int J Cancer (2009) 1.12
A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A (2013) 1.11
IL-12-programmed long-term CD8+ T cell responses require STAT4. J Immunol (2006) 1.11
Phosphorylation of maskin by Aurora-A participates in the control of sequential protein synthesis during Xenopus laevis oocyte maturation. J Biol Chem (2005) 1.11
Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. J Immunol (2006) 1.10
The D-Box-activating domain (DAD) is a new proteolysis signal that stimulates the silent D-Box sequence of Aurora-A. EMBO Rep (2002) 1.09
Aurora B -TACC1 protein complex in cytokinesis. Oncogene (2004) 1.07
Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases. Gynecol Oncol (2002) 1.06
Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy. Immunol Invest (2006) 1.05
Immunologic approaches to ovarian cancer treatment. J Clin Oncol (2007) 1.05
Spatio-temporal expression patterns of aurora kinases a, B, and C and cytoplasmic polyadenylation-element-binding protein in bovine oocytes during meiotic maturation. Biol Reprod (2007) 1.04
Centrosome separation: respective role of microtubules and actin filaments. Biol Cell (2002) 1.04
Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes Control (2013) 1.03
Clinical and pathological predictive factors in women with adult-type granulosa cell tumor of the ovary. Int J Gynecol Pathol (2007) 1.03
Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation. Cancer Immunol Immunother (2012) 1.03
Withaferin A targets intermediate filaments glial fibrillary acidic protein and vimentin in a model of retinal gliosis. J Biol Chem (2010) 1.03
Aurora A is involved in central spindle assembly through phosphorylation of Ser 19 in P150Glued. J Cell Biol (2013) 1.02
Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. Gynecol Oncol (2009) 1.02
Pathogenesis of mediastinal paravertebral müllerian cysts of Hattori: developmental endosalpingiosis-müllerianosis. Int J Gynecol Pathol (2010) 1.01
OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Int J Oncol (2006) 1.01
Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett (2005) 1.01
Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages. J Carcinog (2007) 1.01
IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am J Clin Pathol (2010) 1.01
Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody. J Clin Pathol (2006) 1.01
XAF1 mediates tumor necrosis factor-alpha-induced apoptosis and X-linked inhibitor of apoptosis cleavage by acting through the mitochondrial pathway. J Biol Chem (2007) 1.00
Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics Clin Appl (2009) 1.00
Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. J Exp Med (2013) 0.99
Estrogen-induced hypothalamic synaptic plasticity and pituitary sensitization in the control of the estrogen-induced gonadotrophin surge. Reprod Sci (2007) 0.99
Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs. Clin Immunol (2007) 0.99
A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma. Clin Cancer Res (2012) 0.99
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet (2013) 0.99
Novel genetic variants in miR-191 gene and familial ovarian cancer. BMC Cancer (2010) 0.98
Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol Oncol (2005) 0.98
Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. J Proteome Res (2011) 0.98
Economic analysis of centralized vs. decentralized electronic data capture in multi-center clinical studies. Stud Health Technol Inform (2011) 0.97
Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1. J Chem Inf Model (2008) 0.97
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med (2012) 0.96
Cdk1, Plks, Auroras, and Neks: the mitotic bodyguards. Adv Exp Med Biol (2008) 0.96
Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. Int J Cancer (2006) 0.96
Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun (2008) 0.96
DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11. Epigenetics (2013) 0.96
PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest (2012) 0.95
ASAP is a novel substrate of the oncogenic mitotic kinase Aurora-A: phosphorylation on Ser625 is essential to spindle formation and mitosis. Hum Mol Genet (2007) 0.95
Nucleophosmin/B23 activates Aurora A at the centrosome through phosphorylation of serine 89. J Cell Biol (2012) 0.95
Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression. J Ovarian Res (2011) 0.95
Localization of aurora A and aurora B kinases during interphase: role of the N-terminal domain. Cell Cycle (2008) 0.95
Molecular basis of the selectivity of the immunoproteasome catalytic subunit LMP2-specific inhibitor revealed by molecular modeling and dynamics simulations. J Phys Chem B (2010) 0.95